{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:15:52Z","timestamp":1786947352326,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jchromb.2024.124123","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T16:23:30Z","timestamp":1712679810000},"page":"124123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Derivatization-free determination of chiral plasma pharmacokinetics of MDMA and its enantiomers"],"prefix":"10.1016","volume":"1238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0874-4875","authenticated-orcid":false,"given":"Dino","family":"Luethi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Straumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Thomann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidora","family":"Avedisian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Duthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2024.124123_b0005","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat. Med"},{"key":"10.1016\/j.jchromb.2024.124123_b0010","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med"},{"key":"10.1016\/j.jchromb.2024.124123_b0015","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/0269881119844185","article-title":"Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems","volume":"33","author":"Luethi","year":"2019","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.jchromb.2024.124123_b0020","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","article-title":"Pharmacological characterization of designer cathinones in vitro","volume":"168","author":"Simmler","year":"2013","journal-title":"Br. J. Pharmacol"},{"key":"10.1016\/j.jchromb.2024.124123_b0025","doi-asserted-by":"crossref","first-page":"e0150955","DOI":"10.1371\/journal.pone.0150955","article-title":"Impact of cytochrome P450 2D6 function on the chiral blood plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites in humans","volume":"11","author":"Steuer","year":"2016","journal-title":"Plos One"},{"key":"10.1016\/j.jchromb.2024.124123_b0030","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1124\/dmd.115.066340","article-title":"Chiral plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine and its phase I and II metabolites following controlled administration to humans","volume":"43","author":"Steuer","year":"2015","journal-title":"Drug. Metab. Dispos"},{"key":"10.1016\/j.jchromb.2024.124123_b0035","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/dta.1740","article-title":"Development and validation of an LC-MS\/MS method after chiral derivatization for the simultaneous stereoselective determination of methylenedioxy-methamphetamine (MDMA) and its phase I and II metabolites in human blood plasma","volume":"7","author":"Steuer","year":"2015","journal-title":"Drug. Test. Anal"},{"key":"10.1016\/j.jchromb.2024.124123_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115768","article-title":"Development of enantioselective high-performance liquid chromatography-tandem mass spectrometry method for the quantitative determination of 3,4-methylenedioxy-methamphetamine (MDMA) and its phase-1 metabolites in human biological fluids","volume":"238","author":"Lo Faro","year":"2024","journal-title":"J. Pharm. Biomed. Anal"},{"key":"10.1016\/j.jchromb.2024.124123_b0045","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1124\/jpet.109.156174","article-title":"Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice","volume":"331","author":"Murnane","year":"2009","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.jchromb.2024.124123_b0050","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1124\/jpet.109.150573","article-title":"Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations","volume":"329","author":"Fantegrossi","year":"2009","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.jchromb.2024.124123_b0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00213-017-4812-5","article-title":"(\u00b1)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA","volume":"235","author":"Pitts","year":"2018","journal-title":"Psychopharmacology (berl)"},{"key":"10.1016\/j.jchromb.2024.124123_b0060","unstructured":"U.S. Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry, 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf (accessed 23.01.2024)."},{"key":"10.1016\/j.jchromb.2024.124123_b0065","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/bmc.3176","article-title":"Liquid chromatography\u2013tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma","volume":"28","author":"Luethi","year":"2014","journal-title":"Biomed. Chromatogr"},{"key":"10.1016\/j.jchromb.2024.124123_b0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchromb.2013.06.030","article-title":"Liquid chromatography\u2013tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma","volume":"934","author":"Luethi","year":"2013","journal-title":"J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci"},{"key":"10.1016\/j.jchromb.2024.124123_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114980","article-title":"Development and validation of an LC\u2013MS\/MS method for the quantification of mescaline and major metabolites in human plasma","volume":"220","author":"Thomann","year":"2022","journal-title":"J. Pharm. Biomed. Anal"},{"key":"10.1016\/j.jchromb.2024.124123_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123534","article-title":"Liquid chromatography\u2013tandem mass spectrometry method for the bioanalysis of N, N-dimethyltryptamine (DMT) and its metabolites DMT-N-oxide and indole-3-acetic acid in human plasma","volume":"1213","author":"Luethi","year":"2022","journal-title":"J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci"},{"key":"10.1016\/j.jchromb.2024.124123_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122486","article-title":"Development and validation of an LC\u2013MS\/MS method for the bioanalysis of psilocybin's main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma","volume":"1164","author":"Kolaczynska","year":"2021","journal-title":"J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci"},{"key":"10.1016\/j.jchromb.2024.124123_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2024.124104","article-title":"Development and validation of an LC-MS\/MS method for quantifying diamorphine and its major metabolites 6-monoacetylmorphine, morphine, morphine-3-glucuronide, and morphine-6-glucuronide in human plasma","volume":"1237","author":"Thomann","year":"2024","journal-title":"J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci"},{"key":"10.1016\/j.jchromb.2024.124123_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116076","article-title":"Optimization of enantioselective high-performance liquid chromatography-tandem mass spectrometry method for the quantitative determination of 3,4-methylenedioxy-methamphetamine (MDMA) and its phase-1 metabolites in human biological fluids","volume":"243","author":"Sprega","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2024.124123_b0100","first-page":"1001","article-title":"Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine)","volume":"32","author":"Pizarro","year":"2004","journal-title":"Drug. Metab. Dispos"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224001314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224001314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T11:13:46Z","timestamp":1714302826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023224001314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":20,"alternative-id":["S1570023224001314"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124123","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Derivatization-free determination of chiral plasma pharmacokinetics of MDMA and its enantiomers","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"124123"}}